H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright lifted the price target on Century Therapeutics, Inc. (NASDAQ:IPSC) to $5 from $2 on April 21, maintaining a Buy rating on the shares. The firm told investors in a research note that Vertex has shown stem-cell islets can work and Sana has shown hypoimmune-edited islets can survive, adding that Century Therapeutics, Inc. (NASDAQ:IPSC) is attempting to combine these two proof points in CNTY-813. It added CNTY-813 into its model, with a 20% probability of approval and peak sales of $3.4 billion across the globe.

For additional reference, in its full year 2025 results, Century Therapeutics, Inc. (NASDAQ:IPSC) reported that its cash, cash equivalents, and marketable securities are $117.1 million as of December 31, 2025, as compared to $220.1 million as of December 31, 2024. In addition, collaboration revenue generated by the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the prior year period.

Century Therapeutics, Inc. (NASDAQ:IPSC) develops off-the-shelf cell therapies to advance the course of cancer care, with a focus on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.